Cargando…

Management and outcomes of intraductal papillary mucinous neoplasms

BACKGROUND: This study evaluated the outcome and survival of patients with radiologically suspected intraductal papillary mucinous neoplasms (IPMNs). METHODS: IPMN management was reviewed according to Fukuoka risk factors and IPMN localization, differentiating main‐duct (MD), mixed‐type (MT) and bra...

Descripción completa

Detalles Bibliográficos
Autores principales: Hipp, J., Mohamed, S., Pott, J., Sick, O., Makowiec, F., Hopt, U. T., Fichtner‐Feigl, S., Wittel, U. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677100/
https://www.ncbi.nlm.nih.gov/pubmed/31388641
http://dx.doi.org/10.1002/bjs5.50156
_version_ 1783440885722120192
author Hipp, J.
Mohamed, S.
Pott, J.
Sick, O.
Makowiec, F.
Hopt, U. T.
Fichtner‐Feigl, S.
Wittel, U. A.
author_facet Hipp, J.
Mohamed, S.
Pott, J.
Sick, O.
Makowiec, F.
Hopt, U. T.
Fichtner‐Feigl, S.
Wittel, U. A.
author_sort Hipp, J.
collection PubMed
description BACKGROUND: This study evaluated the outcome and survival of patients with radiologically suspected intraductal papillary mucinous neoplasms (IPMNs). METHODS: IPMN management was reviewed according to Fukuoka risk factors and IPMN localization, differentiating main‐duct (MD), mixed‐type (MT) and branch‐duct (BD) IPMNs. Perioperative results were compared with those of patients undergoing resection of pancreatic ductal adenocarcinoma (PDAC) over the same interval (2010–2014). Overall (OS) and disease‐specific (DSS) survival rates were calculated and subgroups compared. RESULTS: Of 142 patients with IPMNs, 26 had MD‐IPMN, eight had MT‐IPMN and 108 had BD‐IPMN. Some 74 per cent of patients with MD‐ and MT‐IPMN were managed by primary resection, whereas this was used in only 27·8 per cent of those with BD‐IPMN. The risk of secondary resection and malignant transformation for BD‐IPMNs smaller than 20 mm was 8 and 2 per cent respectively during follow‐up. Pancreatic head resection of IPMNs was associated with an increased risk of postoperative pancreatic fistula grade B/C compared with resection of PDAC (12 of 33 (36 per cent) versus 41 of 221 (18·6 per cent) respectively; P = 0·010), and greater morbidity and mortality (Clavien–Dindo grade III: 15 of 33 (45 per cent) versus 56 of 221 (25·3 per cent) respectively; grade IV: 1 (3 per cent) versus 7 (3·2 per cent); grade V: 2 (6 per cent) versus 2 (0·9 per cent); P = 0·008). Five‐year OS and DSS rates in patients with MD‐IPMN were worse than those for MT‐ and BD‐IPMN (OS: 44, 86 and 97·4 per cent respectively, P < 0·001; DSS: 60, 100 and 98·6 per cent; P < 0·001). Patients with invasive IPMN had worse OS and DSS rates than those with non‐invasive dysplasia (OS: IPMN‐carcinoma (10 patients) 33 per cent, high‐grade dysplasia 100 per cent, intermediate‐grade dysplasia 63 per cent, low grade‐dysplasia 100 per cent, P < 0·001; DSS: IPMN‐carcinoma 43 per cent, all grades of dysplasia 100 per cent, P < 0·001). Patients with high‐risk stigmata had poorer survival than those without risk factors (OS: high‐risk stigmata (35 patients) 55 per cent, worrisome features (31) 95 per cent, no risk factors (76) 100 per cent, P < 0·001; DSS: 71, 100 and 100 per cent respectively, P < 0·001). CONCLUSION: The risk of malignant transformation was very low for BD‐IPMNs, but the development of high‐risk stigmata was associated with disease‐specific mortality. Patients with IPMN had greater morbidity after resection than those having resection of PDAC.
format Online
Article
Text
id pubmed-6677100
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-66771002019-08-06 Management and outcomes of intraductal papillary mucinous neoplasms Hipp, J. Mohamed, S. Pott, J. Sick, O. Makowiec, F. Hopt, U. T. Fichtner‐Feigl, S. Wittel, U. A. BJS Open Original Articles BACKGROUND: This study evaluated the outcome and survival of patients with radiologically suspected intraductal papillary mucinous neoplasms (IPMNs). METHODS: IPMN management was reviewed according to Fukuoka risk factors and IPMN localization, differentiating main‐duct (MD), mixed‐type (MT) and branch‐duct (BD) IPMNs. Perioperative results were compared with those of patients undergoing resection of pancreatic ductal adenocarcinoma (PDAC) over the same interval (2010–2014). Overall (OS) and disease‐specific (DSS) survival rates were calculated and subgroups compared. RESULTS: Of 142 patients with IPMNs, 26 had MD‐IPMN, eight had MT‐IPMN and 108 had BD‐IPMN. Some 74 per cent of patients with MD‐ and MT‐IPMN were managed by primary resection, whereas this was used in only 27·8 per cent of those with BD‐IPMN. The risk of secondary resection and malignant transformation for BD‐IPMNs smaller than 20 mm was 8 and 2 per cent respectively during follow‐up. Pancreatic head resection of IPMNs was associated with an increased risk of postoperative pancreatic fistula grade B/C compared with resection of PDAC (12 of 33 (36 per cent) versus 41 of 221 (18·6 per cent) respectively; P = 0·010), and greater morbidity and mortality (Clavien–Dindo grade III: 15 of 33 (45 per cent) versus 56 of 221 (25·3 per cent) respectively; grade IV: 1 (3 per cent) versus 7 (3·2 per cent); grade V: 2 (6 per cent) versus 2 (0·9 per cent); P = 0·008). Five‐year OS and DSS rates in patients with MD‐IPMN were worse than those for MT‐ and BD‐IPMN (OS: 44, 86 and 97·4 per cent respectively, P < 0·001; DSS: 60, 100 and 98·6 per cent; P < 0·001). Patients with invasive IPMN had worse OS and DSS rates than those with non‐invasive dysplasia (OS: IPMN‐carcinoma (10 patients) 33 per cent, high‐grade dysplasia 100 per cent, intermediate‐grade dysplasia 63 per cent, low grade‐dysplasia 100 per cent, P < 0·001; DSS: IPMN‐carcinoma 43 per cent, all grades of dysplasia 100 per cent, P < 0·001). Patients with high‐risk stigmata had poorer survival than those without risk factors (OS: high‐risk stigmata (35 patients) 55 per cent, worrisome features (31) 95 per cent, no risk factors (76) 100 per cent, P < 0·001; DSS: 71, 100 and 100 per cent respectively, P < 0·001). CONCLUSION: The risk of malignant transformation was very low for BD‐IPMNs, but the development of high‐risk stigmata was associated with disease‐specific mortality. Patients with IPMN had greater morbidity after resection than those having resection of PDAC. John Wiley & Sons, Ltd 2019-03-21 /pmc/articles/PMC6677100/ /pubmed/31388641 http://dx.doi.org/10.1002/bjs5.50156 Text en © 2019 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Hipp, J.
Mohamed, S.
Pott, J.
Sick, O.
Makowiec, F.
Hopt, U. T.
Fichtner‐Feigl, S.
Wittel, U. A.
Management and outcomes of intraductal papillary mucinous neoplasms
title Management and outcomes of intraductal papillary mucinous neoplasms
title_full Management and outcomes of intraductal papillary mucinous neoplasms
title_fullStr Management and outcomes of intraductal papillary mucinous neoplasms
title_full_unstemmed Management and outcomes of intraductal papillary mucinous neoplasms
title_short Management and outcomes of intraductal papillary mucinous neoplasms
title_sort management and outcomes of intraductal papillary mucinous neoplasms
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677100/
https://www.ncbi.nlm.nih.gov/pubmed/31388641
http://dx.doi.org/10.1002/bjs5.50156
work_keys_str_mv AT hippj managementandoutcomesofintraductalpapillarymucinousneoplasms
AT mohameds managementandoutcomesofintraductalpapillarymucinousneoplasms
AT pottj managementandoutcomesofintraductalpapillarymucinousneoplasms
AT sicko managementandoutcomesofintraductalpapillarymucinousneoplasms
AT makowiecf managementandoutcomesofintraductalpapillarymucinousneoplasms
AT hoptut managementandoutcomesofintraductalpapillarymucinousneoplasms
AT fichtnerfeigls managementandoutcomesofintraductalpapillarymucinousneoplasms
AT wittelua managementandoutcomesofintraductalpapillarymucinousneoplasms